Pharma invented the term 'discontinuation syndrome' to hide that SSRI antidepressants cause real withdrawal — affecting 33-56% of users

SSRI Withdrawal: How a Pharmaceutical Term Obscured a Widespread Problem

For decades, millions of people were told that stopping selective serotonin reuptake inhibitors—SSRIs, the most commonly prescribed class of antidepressants—would not cause withdrawal. The drugs were marketed as non-addictive, fundamentally different from benzodiazepines or other medications known to produce dependence. Patients who experienced severe symptoms when discontinuing these medications were often told what they were experiencing wasn't "real" withdrawal—it was something else entirely: "discontinuation syndrome."

The problem is this term appears to have been strategically created to obscure a reality that pharmaceutical companies wanted to minimize.

Before 1997, the term "discontinuation syndrome" was virtually nonexistent in medical literature. A search of published research shows the phrase used exactly once prior to that year. Then, in 1997, Eli Lilly—the manufacturer of Prozac—sponsored a journal supplement that formally introduced and promoted the term as the proper medical language for describing what happens when patients stop taking SSRIs. That single sponsored publication changed everything. By the end of 1997 alone, the term appeared 12 times in medical literature. Within years, it had become standard terminology across the psychiatric establishment.

The significance of this linguistic shift cannot be overstated. The word "withdrawal" carries specific clinical and legal implications. It suggests a physical dependence, acknowledged risks, and informed consent obligations. "Discontinuation syndrome," by contrast, sounds temporary and mild—a mere adjustment rather than a serious medical event. Patients reading about "discontinuation syndrome" receive a fundamentally different impression than if they read about "SSRI withdrawal."

For nearly two decades, this terminology held. Psychiatrists and general practitioners told patients these medications were safe to stop. Pharmaceutical marketing materials emphasized non-addictive profiles. messages reinforced the message. But the clinical reality patients experienced contradicted .